How GLOW blend works
An unapproved skin-and-recovery blend with no human combination study found.
Also called: GLOW stack, GHK-Cu/BPC/TB blend.
Community blends · Unapproved three-ingredient peptide and copper mixture; ratios vary.
The proposed idea combines copper-linked repair signals with BPC-157 and TB4-related signals. Ingredient studies suggest changes in collagen, blood vessels and cell movement. No experiment in people shows that this trio works together or that mixing improves results.
- GHK-Cu: connective-tissue remodeling: Increased collagen and other repair material in rat wound chambers.
- BPC-157: vessel-growth signaling: Changed VEGFR2-related signals in animals and cells.
- Full-length TB4: cell movement: Animal wound effects do not validate shorter TB-500 fragments or a mixed vial.
Half-life: Unknown for the blend; no human combination pharmacokinetic study found.
Related to GLOW blend (GHK-Cu + BPC-157 + TB-500)
- KLOW blend: GLOW plus KPV: a four-ingredient community blend with no human study of the combination found.
- Wolverine stack (BPC-157 + TB-500): An unapproved recovery blend with no controlled human trial of the premixed product.
- Semaglutide: A GLP-1 medicine with strong weight, glucose, heart and kidney evidence; dose and formulation matter.
- KPV: An alpha-MSH fragment studied for gut inflammation in animals, with no human dosing trial.
Sources
- 21 CFR 216.23 — Bulk drug substances that can be used to compound drug products in accordance with section 503A of the Federal Food, Drug, and Cosmetic Act., Office of the Federal Register · eCFR · 2026
- 503B Bulk Drug Substances List, FDA · FDA · 2026
- Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act, FDA · FDA · 2026
- Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act, FDA · FDA · 2026
- Cellulitis, NHS · NHS · 2026
- Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks, FDA · FDA · 2026
- Federal Register: nonbinding draft HHS interim policy, October 30 2026, 2026
- HHS 503A peptide interim enforcement policy and conditions, October 30 2026, 2026
- July 23-24, 2026, Meeting of the Pharmacy Compounding Advisory Committee – FDA Briefing Document for BPC-157-Related Bulk Drug Substances (BPC-157 (free base) and BPC-157 acetate), FDA · 2026
- July 23-24, 2026, Meeting of the Pharmacy Compounding Advisory Committee – FDA Briefing Document for TB-500-Related Bulk Drug Substances (TB-500 (free base) and TB-500 acetate), FDA · FDA · 2026
- July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee - 07/23/2026, FDA · FDA · 2026
- Medicines, European Medicines Agency · European Medicines Agency · 2026
- MHRA Products | Home, MHRA · MHRA · 2026
- The 2026 Prohibited List, World Anti-Doping Agency · WADA · 2026
- Therapeutic Goods (Poisons Standard—October 2026) Instrument 2026, Australian Government · Australian Government · 2026
Sources checked: 2026-10-18.
Information only, not medical advice. Peptifacts does not sell anything and does not link to sellers.